Cookie Img
Send SMS    Call Me Free
Home » Products » Anti-Cancer Products » E-HEP

E-HEP

E-HEP
E-HEP
Product Code : #0150
Brand Name : E-HEP (Sofosbuvir)
Product Specifications
  • Formulations Type
  • Chemical Drug
  • Formulations Form
  • Tablets
  • Gender/Age Group
  • Adult
Product Description

Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used for the treatment of hepatitis C.[1] It is only recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir, daclatasvir, or velpatasvir.[3][4] Cure rates are 30 to 97% depending on the type of hepatitis C virus involved.[5] Safety during pregnancy is unclear; while, some of the medications used in combination may result in harm to the baby.[5] It is taken by mouth.[1]

Common side effects include feeling tired, headache, nausea, and trouble sleeping.[1] Side effects are generally more common in interferon-containing regimens.[6]:7 Sofosbuvir may reactivate hepatitis B in those who have been previously infected.[7] In combination with ledipasvir, daclatasvir or simeprevir it is not recommended with amiodarone due to the risk of an abnormally slow heartbeat.[6] Sofosbuvir is in the nucleotide analog family of medication and works by blocking the hepatitis C NS5B protein.[8]

Sofosbuvir was discovered in 2007 and approved for medical use in the United States in 2013.[3][9] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[10] As of 2016 a 12-week course of treatment costs about $84,000 in the United States, $53,000 in the United Kingdom, $45,000 in Canada, and $483 in India.[11] Over 60,000 people were treated with sofosbuvir in its first 30 weeks being sold in the United States.[12]

Medical uses

Sofosbuvir (Sovaldi) 400mg

Initial HCV treatment

In 2016, the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America jointly published a recommendation for the management of hepatitis C. In this recommendation, sofosbuvir used in combination with other drugs is part of all first-line treatments for HCV genotypes 1, 2, 3, 4, 5, and 6, and is also part of some second-line treatments.[13] Sofosbuvir in combination with velpatasvir is recommended for all genetypes with a cure rate greater than 90%, and close to 100% in most cases. The duration of treatment is typically 12 weeks.[13][14]

Sofosbuvir is also used with other medications and longer treatment durations, depending on specific circumstances, genotype and cost-effectivenessâ€â€œbased perspective. For example, for the treatment of genotypes 1, 4, 5, and 6 hepatitis C infections, sofosbuvir can be used in combination with the viral NS5A inhibitor ledipasvir. In genotype 2 and 3 HCV infections, sofosbuvir can be used in combination with daclatasvir. For the treatment of cases with cirrhosis or liver transplant patients, weight-based ribavirin is sometimes added. Peginterferon with or without sofosbuvir is no longer recommended in an initial HCV treatment.[13]

Compared to previous treatments, sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy.[15][16][17] Sofosbuvir allows most people to be treated successfully without the use of peginterferon, an injectable drug with severe side effects that is a key component of older drug combinations for the treatment of hepatitis C virus.

Trade Information
  • Payment Terms
  • Cash on Delivery (COD), Cash Advance (CA), Cash in Advance (CID), Delivery Point (DP), Western Union
  • Sample Available
  • Yes
  • Main Export Market(s)
  • Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
  • Main Domestic Market
  • All India

AMBICA PHARMA

Contact Us

( *represents compulsory fields )

Tips on getting accurate quotes. Please include product name, order quantity, usage, special requests if any in your inquiry.



AMBICA PHARMA All Rights Reserved.